Alnylam Pharmaceuticals Stock Buy Hold or Sell Recommendation
| ALNY Stock | USD 243.86 1.34 0.55% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Alnylam Pharmaceuticals is 'Hold'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Alnylam Pharmaceuticals given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Alnylam Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Alnylam Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy Alnylam Stock please use our How to Invest in Alnylam Pharmaceuticals guide. In addition, we conduct extensive research on individual companies such as Alnylam and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Alnylam Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Alnylam |
Execute Alnylam Pharmaceuticals Buy or Sell Advice
The Alnylam recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Alnylam Pharmaceuticals. Macroaxis does not own or have any residual interests in Alnylam Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Alnylam Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Alnylam Pharmaceuticals Trading Alerts and Improvement Suggestions
| Alnylam Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 2.25 B. Net Loss for the year was (278.16 M) with profit before overhead, payroll, taxes, and interest of 1.92 B. | |
| Alnylam Pharmaceuticals currently holds about 2.27 B in cash with (8.31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 18.41. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from benzinga.com: Heres How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years |
Alnylam Pharmaceuticals Returns Distribution Density
The distribution of Alnylam Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Alnylam Pharmaceuticals' future price movements. The chart of the probability distribution of Alnylam Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Alnylam Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Alnylam Pharmaceuticals returns is essential to provide solid investment advice for Alnylam Pharmaceuticals.
| Mean Return | 0.09 | Value At Risk | -3.19 | Potential Upside | 4.37 | Standard Deviation | 2.34 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Alnylam Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Alnylam Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument, such as Alnylam Pharmaceuticals, soars without any apparent reason? This usually happens because many institutional investors are aggressively trading Alnylam Pharmaceuticals back and forth among themselves.
| Shares | State Street Corp | 2024-12-31 | 3.4 M | T. Rowe Price Associates, Inc. | 2024-12-31 | 3.3 M | Norges Bank | 2024-12-31 | 2.5 M | Geode Capital Management, Llc | 2024-12-31 | 2.2 M | American Century Companies Inc | 2024-12-31 | 1.6 M | Groupama Asset Management | 2024-12-31 | 1.5 M | Orbis Allan Gray Ltd | 2024-12-31 | 1.5 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 1.4 M | Winslow Capital Management, Llc | 2024-09-30 | 961.6 K | Capital World Investors | 2024-12-31 | 16.6 M | Fmr Inc | 2024-12-31 | 13.5 M |
Alnylam Pharmaceuticals Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (50.6M) | 323.1M | 46.4M | (53.7M) | 153.8M | 161.5M | |
| Free Cash Flow | (685.3M) | (718.1M) | (613.3M) | 41.9M | (42.6M) | (44.7M) | |
| Depreciation | 74.4M | 89.7M | 85.6M | 97.0M | 56.7M | 59.5M | |
| Other Non Cash Items | 95.8M | 174.2M | 309.2M | 214.9M | 47.9M | 53.0M | |
| Capital Expenditures | 70.4M | 76.4M | 72.1M | 62.2M | 34.3M | 39.9M | |
| Net Income | (858.3M) | (852.8M) | (1.1B) | (440.2M) | (278.2M) | (292.1M) | |
| End Period Cash Flow | 499.0M | 822.2M | 868.6M | 814.9M | 968.7M | 1.0B | |
| Change To Netincome | 201.8M | 156.7M | 223.4M | 307.7M | 353.9M | 371.6M | |
| Change To Inventory | (35.4M) | (26.4M) | (34.1M) | 18.4M | 13.6M | 14.3M | |
| Investments | (334.0M) | (192.6M) | 169.4M | (235.6M) | (116.8M) | (122.7M) | |
| Change Receivables | (24.2M) | (56.2M) | (101.8M) | (45.6M) | (41.0M) | (39.0M) |
Alnylam Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Alnylam Pharmaceuticals or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Alnylam Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Alnylam stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.08 | |
β | Beta against Dow Jones | 0.93 | |
σ | Overall volatility | 2.31 | |
Ir | Information ratio | 0.04 |
Alnylam Pharmaceuticals Volatility Alert
Alnylam Pharmaceuticals has relatively low volatility with skewness of 1.1 and kurtosis of 4.29. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Alnylam Pharmaceuticals' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Alnylam Pharmaceuticals' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Alnylam Pharmaceuticals Fundamentals Vs Peers
Comparing Alnylam Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Alnylam Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Alnylam Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Alnylam Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Alnylam Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Alnylam Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Alnylam Pharmaceuticals to competition |
Note: Disposition of 25000 shares by Garg Pushkal of Alnylam Pharmaceuticals at 88.95 subject to Rule 16b-3 [view details]
Alnylam Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Alnylam . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
| Accumulation Distribution | 21593.26 | |||
| Daily Balance Of Power | (0.16) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 247.52 | |||
| Day Typical Price | 246.3 | |||
| Price Action Indicator | (4.33) | |||
| Period Momentum Indicator | (1.34) | |||
| Relative Strength Index | 43.66 |
About Alnylam Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Alnylam Pharmaceuticals? Buying financial instruments such as Alnylam Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Alnylam Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Marketing Thematic Idea Now
Marketing
Companies providing marketing and public relation (PR) services as well as news and media distribution. The Marketing theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Marketing Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.